๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Treatment
Clinical trial register · China

Treatment Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Tianjin 17 Shanghai 4 Beijing 4 Nanjing 2 Xi'an 1
Narrow the registerReset
Recruitment status
Phase
Site location
Tianjin17 Shanghai4 Beijing4 Nanjing2 Xi'an1
All 6 locations
Target enrolment
to

Treatment trials in China

29 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)
NCT07362238Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
122
Tianjin
2026-03
Recruiting
Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
NCT07362199Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2026-03
Recruiting
Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
NCT07234019Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
160
Tianjin
2026-01-28
Recruiting
Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
NCT07297563Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
160
Tianjin
2026-01-20
Recruiting
Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML
NCT06611839AML, IDH1 Mutation, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
23
Tianjin
2025-10-17
Recruiting
Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP)
NCT07063199Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
30
Tianjin
2025-08
Recruiting
An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia
NCT06799611Immune Thrombocytopenia (ITP), Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2025-03-03
Recruiting
A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia
NCT06776510Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
20
Tianjin
2025-01-15
Recruiting
A Clinical Study of Personalized Self-DC Vaccine Targeting Neoantigen in Treatment of Advanced Solid Tumor
NCT06682117Treatment, Neoantigen, Vaccine, Solid Tumor Cancer
Fudan University
Not applicable
9
Shanghai
2024-11-15
Recruiting
A Trial of Chinese Traditional Medicine Combining With Intradermal Acupuncture for Treating Precocious Puberty
NCT06510764Precocious Puberty, Treatment, Alternative Medicine, Acupuncture
Children's Hospital of Fudan University
Phase 3
170
Shanghai
2024-09-15
Recruiting
Clinical Study on the Effectiveness of Diverse Segments Defocus Optimization in Spectacle Lenses for Slowing Myopia Progression
NCT07323251Children With Myopia, Treatment, Multizone Lens Design for Myopic Defocus, Visual Quality
Beijing Tongren Hospital
Not applicable
120
Beijing
2024-08-02
Recruiting
Anti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP)
NCT06838962Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
30
Tianjin
2024-08-01
Recruiting
Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia
NCT06281327Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
60
Tianjin
2024-03-01
Active, closed
A Randomized, Double-blind, Placebo-controlled, and Multi-center Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia
NCT06199089Immune Thrombocytopenia, Treatment
DrugCM313
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
45
Tianjin
2024-01-16
Recruiting
The Safety and Efficacy of Single Antiplatelet Therapy After Pipeline Flex with Shield for Intracranial Aneurysms
NCT06474884Treatment
Xuanwu Hospital, Beijing
Observational
165
Beijing
2024-01-01
Recruiting
Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)
NCT06168851Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
60
Tianjin
2023-12-28
Recruiting
A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)
NCT06094881Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
60
Tianjin
2023-12-01
Recruiting
Anti-CD38 Antibody Treating Evans Syndrome
NCT06014775Evan Syndrome, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
10
Tianjin
2023-12-01
Recruiting
A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Immune Thrombocytopenia
NCT05995054Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
110
Tianjin
2023-08-28
Recruiting
Efficacy Safety BaiDiZiYin ShenQiYiFei Adjunctive Treatments Pulmonary Tuberculosis
NCT06403943Adjuvant, Treatment, Tuberculosis
Beijing Chest Hospital
Phase 4
292
Beijing
2023-05-29
Recruiting
A Study on Diagnosis and Treatment Strategies for Atlantoaxial Dislocation
NCT06233539Atlantoaxial Dislocation, Treatment, Diagnostic
Peking University Third Hospital
Observational
3,000
Beijing
2022-12-01
Active, closed
Rituximab for the Treatment of New-onset AChR-Myasthenia Gravis
NCT07071246Treatment
Tang-Du Hospital
Not applicable
30
Xi'an
2022-08-01
Recruiting
A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia
NCT05214391Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
30
Tianjin
2022-02-15
Recruiting
Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia
NCT05199909Antiphospholipid Syndrome, Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
10
Tianjin
2022-01-25
Recruiting
A Pilot Study in Severe Patients With Takayasu Arteritis.
NCT04300686Takayasu Arteritis, Tocilizumab, Adalimumab, Treatment
Shanghai Zhongshan Hospital
Phase 4
40
Shanghai
2020-03-01
Recruiting
Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis
NCT04592640Chronic Kidney Diseases, Calciphylaxis, Calcific Uremic Arteriolopathy, Treatment
The First Affiliated Hospital with Nanjing Medical University
Phase EARLY_PHASE1
9
Nanjing
2018-09-17
Recruiting
Effects of Different Treatment Schemes on the Regulation and Recurrence of Graves' Disease
NCT05461820Graves Disease, Relapse, Treatment, Drug Withdrawal
The First Affiliated Hospital with Nanjing Medical University
Phase 4
240
Nanjing
2018-05-01
Recruiting
Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component โ‰ฅ 20%
NCT03351842Chemotherapy, Adjuvant, Lung Adenocarcinoma, Stage I, Treatment, Histological Type of Neoplasm
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
460
Shanghai
2017-09-01
Rows per page Showing 1–29 of 29
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/condition/treatment

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 29 of those studies listing the condition Treatment.

How many Treatment trials are recruiting in China?

27 of the 29 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 0 have not yet opened recruitment, 2 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Treatment), 29 studies
PhaseStudiesRecruitingShare
Phase 2171658.6%
Not applicable3210.3%
Phase 43310.3%
Observational226.9%
Phase 1/2226.9%
Phase 3113.4%
Phase EARLY_PHASE1113.4%

Most active sponsors

Lead sponsors with the most studies (Treatment)
Lead sponsorStudiesRecruiting
Institute of Hematology & Blood Diseases Hospital, China1716
The First Affiliated Hospital with Nanjing Medical University22
Beijing Chest Hospital11
Beijing Tongren Hospital11
Children's Hospital of Fudan University11
Fudan University11
Henan Cancer Hospital11
Peking University Third Hospital11
Shanghai Pulmonary Hospital, Shanghai, China11
Shanghai Zhongshan Hospital11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.